전이성 대장암 : 신규 요법, 미충족 수요 및 TPP 인사이트 리포트(2026년)

Metastatic Colorectal Cancer Emerging Therapy and TPP Insights

Thelansis's "Metastatic Colorectal Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Metastatic Colorectal Cancer Overview

Metastatic colorectal cancer (mCRC), or Stage IV colorectal cancer, occurs when malignant cells originating in the colon or rectum spread to distant organs-most commonly the liver and lungs, and less frequently the peritoneum, brain, and bones. This metastatic progression is the primary driver of mortality in colorectal cancer.

While curative outcomes remain limited in advanced disease, therapeutic advancements have significantly improved overall survival and quality of life. Treatment is highly personalized and guided by tumor biology, molecular profile, and line of therapy, incorporating combinations of:

• Chemotherapy (FOLFOX, FOLFIRI-based regimens)
• Targeted therapies (EGFR inhibitors, VEGF inhibitors, BRAF inhibitors)
• Immunotherapies (particularly in MSI-H/dMMR populations)

In select patients, metastasectomy and liver-directed therapies (ablation, embolization) play a critical role in disease control and potential long-term remission.

Key Highlights

• mCRC represents a high-burden oncology segment, with a substantial proportion of colorectal cancer patients progressing to metastatic disease.
• The drug-treatable patient population remains large and growing, supported by increasing diagnosis rates and improved survival outcomes.
• Treatment paradigm is highly biomarker-driven, with segmentation based on: Tumor sidedness (left vs right) & Molecular status (RAS/BRAF mutations, MSI status)
• RAS mutations account for 45-50% of patients, while BRAF mutations (8-10%) represent a smaller but high-risk subgroup.
• Treatment is structured across multiple lines:
• 1st line: chemo + targeted therapy (EGFR/VEGF)
• 2nd line: therapy switch based on resistance patterns
• 3rd/4th line: later-line targeted agents and salvage therapies

Market Overview

• The mCRC market is valued at $4.3Bn in 2025, projected to reach $6.1Bn by 2035, reflecting a CAGR of 3.5-4%.
• Market growth is driven by: Increasing drug-treatable population (87K to 91K patients), Expanded use of targeted therapies and biologics, Improved treatment sequencing across multiple lines

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Mirati Therapeutics Inc.
• Buzzard Pharmaceuticals
• Parabilis Medicines, Inc.
• Astellas Pharma Inc
• Mirror Biologics, Inc.
• Shanghai Kechow Pharma, Inc.
• Suzhou Teligene Ltd.
• AstraZeneca
• Novartis Pharmaceuticals
• Carina Biotech Limited
• Treos Bio Limited
• Cardiff Oncology
• Alethia Biotherapeutics
• Shanghai EpimAb Biotherapeutics Co., Ltd.
• AbbVie
• Hoffmann-La Roche
• Menarini Group
• Akeso
• Riboscience, LLC.
• Amgen
• Qilu Pharmaceutical Co., Ltd.
• Pfizer
• BioNTech SE
• Arcus Biosciences, Inc.
• BeyondBio Inc.
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Agenus Inc.
• Bristol-Myers Squibb
• Taizhou Mabtech Pharmaceutical Co.,Ltd
• Incyte Biosciences International
• Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
• Hutchison Medipharma Limited
• Hansoh BioMedical R&D Company
• Jiangsu Simcere Pharmaceutical Co., Ltd.
• Luye Pharma Group Ltd.
• Shanghai JMT-Bio Inc.
• Summit Therapeutics
• Erasca, Inc.
• STCube, Inc.
• CytoDyn, Inc.
• Anbogen Therapeutics, Inc.
• Isofol Medical AB
• MedImmune LLC
• Beijing Biotech
• Vedanta Biosciences, Inc.
• Pierre Fabre Medicament
• Compass Therapeutics
• Amal Therapeutics
• MedPacto, Inc.
• PureTech
• IDEAYA Biosciences
• Wugen, Inc.
• Stingray Therapeutics
• Evopoint Biosciences Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)